About Enaltec Labs Private Limited
Data last updated: 18 February 2026
Enaltec Labs Private Limited is a private limited company based in Thane, Maharashtra, India, a subsidiary of La Renon Healthcare Private Limited. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 24 February 2006, the company has been in operation for over 20 years.
Registered with ROC Mumbai under CIN U73100MH2006PTC160020.
Capital: an authorised share capital of ₹112 Cr and a paid-up capital of ₹57 Cr. It is led by directors including Amish Vyas Pravinchandra and Anand Prafulchandra Shah.
Last AGM: 08 September 2025. Financial statements filed for year ended 31 March 2025. Office: Sector 19, Thane, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹169.73 Cr, a growth of 11% compared to the previous year.
The company has a workforce of approximately 286 employees as per the latest available data. It operates as a subsidiary of La Renon Healthcare Private Limited. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Enaltec Labs. As per MCA filings, the company has open charges of ₹76.2 Cr and satisfied charges of ₹320.53 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website enaltec.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address401 4Th Floor Kesar Solitaire, Plot No 5 Sector 19 Sanpada Navi Mumbai, Thane, Maharashtra, India – 400705
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Enaltec Labs Private Limited
Enaltec Labs Private Limited has one previous CIN (Corporate Identification Number): U73100MH2006PTC160020. The current CIN is U21001MH2006PTC160020, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U21001MH2006PTC160020 | Current |
| U73100MH2006PTC160020 | Previous |
Associated Brands with Enaltec Labs Private Limited
Enaltec Labs Private Limited operates one associated brand: Enaltec Labs. These brands represent Enaltec Labs Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Non-oncology APIs are developed and manufactured by Enaltec Labs. | enaltec.com |
Competitors & Alternatives of Enaltec Labs Private Limited
Brands and companies operating in the same space as Enaltec Labs Private Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Enaltec Labs Private Limited
Enaltec Labs Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Enaltec Labs Private Limited
Enaltec Labs Private Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Deloitte Haskins & Sells LLP | blur-value | blur-value | blur-value |
Board of Directors of Enaltec Labs Private Limited
Enaltec Labs Private Limited is currently managed by 6 directors, with 17 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Amish Vyas Pravinchandra
Also directs:
Ai4pharma Tech Limited
|
Additional Director | 20 Jun 2025 | 1 Years 0 Months | Current |
| Anand Prafulchandra Shah | Managing Director | 11 May 2007 | 19 Years 1 Months | Current |
| Vivek Gupta | Nominee Director | 14 Feb 2022 | 4 Years 4 Months | Current |
| Samir Kumar | Nominee Director | 14 Feb 2022 | 4 Years 4 Months | Current |
|
Bhavesh Bansidhar Pujara
Also directs:
Hetero Plasma Sciences Private Limited
|
Additional Director | 30 Dec 2025 | 0 Years 6 Months | Current |
Financials of Enaltec Labs Private Limited FY 2025 filings available
Enaltec Labs Private Limited reported revenue of ₹169.73 Cr (up 11% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Enaltec Labs Private Limited
As of FY 2023, Enaltec Labs Private Limited's shareholding pattern shows 1.64% by promoters, 98.36% by public shareholders. Public shareholders hold the majority stake, reflecting broad public ownership.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Enaltec Labs Private Limited
Enaltec Labs Private Limited has 1 subsidiary company. This group structure data is as of FY 2024. The corporate group structure reflects Enaltec Labs Private Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Enaltec Labs Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Sep 2025 | Others | ₹60 Cr | Open |
| 04 Sep 2025 | Others | ₹15 Cr | Open |
| 29 Sep 2023 | Others | ₹1.2 Cr | Open |
| 30 Dec 2020 | Axis Bank Limited | ₹4.93 Cr | Satisfied |
| 20 May 2019 | Others | ₹17.07 Cr | Satisfied |
Total charge records: 16 View all charges
Employees and EPFO Compliance at Enaltec Labs Private Limited
Enaltec Labs Private Limited has a workforce of 286 employees as of Dec 06, 2024.
Employee Count & EPFO Data of Enaltec Labs Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Enaltec Labs Private Limited
GSTIN & GST Filing Data of Enaltec Labs Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Enaltec Labs Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Enaltec Labs Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Enaltec Labs Private Limited
MSME Payment Delays by Enaltec Labs Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Enaltec Labs Private Limited
Subsidiaries & Group Companies of Enaltec Labs Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Enaltec Labs Private Limited with ownership details.
MCA Filings & Documents of Enaltec Labs Private Limited
MCA Filings & Documents of Enaltec Labs Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Enaltec Labs Private Limited
Frequently Asked Questions about Enaltec Labs Private Limited
Enaltec Labs Private Limited is an active private limited company in the pharma sector based in Thane, Maharashtra, India. It was incorporated on 24 February 2006 (20+ years old) and is registered under CIN U21001MH2006PTC160020. The company has 286 employees.
Enaltec Labs Private Limited reported revenue of ₹169.73 Cr for FY 2025 (up 11.00% YoY).
The current directors of Enaltec Labs Private Limited are:
- Amish Vyas Pravinchandra
- Anand Prafulchandra Shah
- Vivek Gupta
- Samir Kumar
- Mahesh Maljibhai Fuliya
- Bhavesh Bansidhar Pujara
The primary industry of Enaltec Labs Private Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Enaltec Labs Private Limited can be reached at the registered office: 401 4Th Floor Kesar Solitaire, Plot No 5 Sector 19 Sanpada Navi Mumbai, Thane, Maharashtra, India – 400705, or through the website enaltec.com.
The authorised capital is ₹112 Cr, and the paid-up capital is ₹57 Cr.